Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study

Exclusion Criteria

• •Treatment with glucagon-like peptide-1 (GLP-1) agonists in the 3 months prior to study entry
• •Previous treatment with insulin (except for treatment of gestational diabetes or brief treatment with insulin for less than 1 week)
• •Diabetes other than type 2 diabetes (e.g. type 1 diabetes, diabetes secondary to pancreatic disorders, drug or chemical agent intake)
• •Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method)
• •Hospitalized patient (except for routine diabetes check-up)
• •Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to study entry, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study, documented by retina examination, in the 2 years prior to study entry
• •History of sensitivity to the study drugs or to drugs with a similar chemical structure
• •Impaired renal function: creatinine clearance \< 60ml/min
• •Impaired liver function (ALT, AST \> 3 x upper limit of normal range)
• •Severe gastro-intestinal disease
• •Treatment with corticosteroids with potential systemic action within the 3 months prior to study entry
• •Likelihood of requiring treatments during the study which are not permitted
• •Treatment with an investigational product in the 30 days prior to study entry
• •Alcohol or drug abuse within the last 5 years
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.